Metabonomic study of biochemical changes in urinary of type 2 diabetes mellitus patients after the treatment of sulfonylurea antidiabetic drugs based on ultra-performance liquid chromatography/mass spectrometry

2014 ◽  
Vol 29 (1) ◽  
pp. 115-122 ◽  
Author(s):  
Taoguang Huo ◽  
Zhili Xiong ◽  
Xiumei Lu ◽  
Shuang Cai
Keyword(s):  
Diabetes Mellitus ◽  
Mass Spectrometry ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liquid Chromatography ◽  
Ultra Performance Liquid Chromatography ◽  
Biochemical Changes ◽  
Antidiabetic Drugs ◽  
Liquid Chromatography Mass Spectrometry

N-glycosylation profiling of Type 2 diabetes mellitus from baseline to follow-up: an observational study in a Ghanaian population

2021 ◽  
Author(s):  
Eric Adua ◽  
Elham Memarian ◽  
Ebenezer Afrifa-Yamoah ◽  
Alyce Russell ◽  
Irena Trbojević-Akmačić ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liquid Chromatography ◽  
Ultra Performance Liquid Chromatography ◽  
Coefficients Of Variation ◽  
Individual Variations ◽  
Glycan Profiling

Aim: The study sought to determine the patterns of N-glycan profiles among Type 2 diabetes mellitus (T2DM) patients over a 6-month period. Materials & methods: Biochemical and clinical data were obtained from 253 T2DM patients at baseline and follow-up. Ultra-performance liquid chromatography and statistical methods were applied for N-glycan profiling. Results: The coefficients of variation were 28% and 29% at baseline and follow-up, respectively, whereas the range of N-glycan variability was from 11% to 56%. Apart from GP1 (FA2) and GP29 (FA3G3S [3,3,3]3), the intra-individual variations of N-glycan peaks were not statistically significant. Conclusion: N-glycan profiles were stable over 6-month period in T2DM patients and could be used to monitor biochemical changes in relation with T2DM comorbidities.

scholarly journals Assessment of the amino acid profile in Thai patients with type 2 diabetes mellitus using liquid chromatography-mass spectrometry

2020 ◽  
Author(s):  
Natthida Sriboonvorakul ◽  
Wirichada Pan-Ngum ◽  
Kittiyod Poovorawan ◽  
Markus Winterberg ◽  
Joel Tarning ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Mass Spectrometry ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Amino Acid ◽  
Glutamic Acid ◽  
Amino Acid Profile ◽  
Liquid Chromatography Mass Spectrometry ◽  
Subgroup Analyses

Abstract Background Type 2 diabetes mellitus (T2DM) is a global health problem. Early identification of those at risk is necessary to prevent its onset through lifestyle and pharmacologic interventions. T2DM is characterized by metabolic abnormalities, including protein metabolism. Evaluation of the amino acid profile might be beneficial for early assessment. Methods Liquid chromatography-mass spectrometry was performed to separate and quantify plasma amino acids from two groups of Thai individuals, patients with T2DM (n=103) and healthy individuals (n=104). Multivariate analysis was applied to compare free amino acid levels between groups. Subgroup analyses of patients with T2DM were performed to assess the association between amino acid profiles and important T2DM clinical characteristics. Results The multivariate analysis showed that glutamic acid was significantly associated with T2DM (OR 1.113, 95% CI 1.006 to 1.231) and results from the subgroup analyses showed that this correlation was significant in all subgroups of patients (p<0.05). Conclusions This finding needs to be confirmed in larger groups of patients with T2DM to explore glutamic acid as a biomarker for early prevention in particular at-risk groups. An in-depth understanding of the involvement of glutamic acid in T2DM could enhance our understanding of the disease and potentially provide novel interventions.

scholarly journals Xenometabolite signatures in the UC Davis type 2 diabetes mellitus rat model revealed using a metabolomics platform enriched with microbe-derived metabolites

2020 ◽  
Vol 319 (2) ◽  
pp. G157-G169 ◽  
Author(s):  
Kelly E. Mercer ◽  
Laxmi Yeruva ◽  
Lindsay Pack ◽  
James L. Graham ◽  
Kimber L. Stanhope ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Mass Spectrometry ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Rat Model ◽  
Liquid Chromatography Mass Spectrometry ◽  
Sequencing Data ◽  
Diabetes Progression ◽  
Proof Of Principle

We debut a liquid chromatography-mass spectrometry (LC/MS) platform called the XenoScan, which is a metabolomics platform for xenometabolites (nonself-originating metabolites). This assay has 190 in-house standards with the majority enriched for microbe-derived metabolites. As a proof-of-principle, we used the XenoScan to discriminate genetic differences from cecal samples associated with different rat lineages, in addition to characterizing diabetes progression in rat model of type 2 diabetes. Complementing microbial sequencing data with xenometabolites uncovered novel microbial metabolism in targeted organisms.

scholarly journals Cost-effectiveness study of antidiabetic drugs in type 2 diabetes mellitus patients from Mumbai, India

2017 ◽  
Vol 4 (9) ◽  
pp. 3180 ◽  
Author(s):  
Dnyanesh Limaye ◽  
Krishna Todi ◽  
Jay Shroff ◽  
Ashutosh Ramaswamy ◽  
Priyanka Kulkarni ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cross Sectional Study ◽  
Antidiabetic Drugs ◽  
Cross Sectional ◽  
Validated Questionnaire ◽  
The Cost

Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India.Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5). Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness. 

Sign in / Sign up

Export Citation Format

Share Document